NO175309C - Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser - Google Patents

Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser

Info

Publication number
NO175309C
NO175309C NO905120A NO905120A NO175309C NO 175309 C NO175309 C NO 175309C NO 905120 A NO905120 A NO 905120A NO 905120 A NO905120 A NO 905120A NO 175309 C NO175309 C NO 175309C
Authority
NO
Norway
Prior art keywords
alkyl
amino
alkoxy
halogen
therapeutically effective
Prior art date
Application number
NO905120A
Other languages
English (en)
Other versions
NO175309B (no
NO905120L (no
NO905120D0 (no
Inventor
Jacob Berger
Robin D Clark
Richard M Eglen
William L Smith
Klaus K Weinhardt
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23755479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO175309(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NO905120D0 publication Critical patent/NO905120D0/no
Publication of NO905120L publication Critical patent/NO905120L/no
Publication of NO175309B publication Critical patent/NO175309B/no
Publication of NO175309C publication Critical patent/NO175309C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
NO905120A 1989-11-28 1990-11-27 Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser NO175309C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44208289A 1989-11-28 1989-11-28

Publications (4)

Publication Number Publication Date
NO905120D0 NO905120D0 (no) 1990-11-27
NO905120L NO905120L (no) 1991-05-29
NO175309B NO175309B (no) 1994-06-20
NO175309C true NO175309C (no) 1994-09-28

Family

ID=23755479

Family Applications (2)

Application Number Title Priority Date Filing Date
NO905120A NO175309C (no) 1989-11-28 1990-11-27 Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser
NO2005023C NO2005023I2 (no) 1989-11-28 2005-09-21 Palonosetron HCI

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005023C NO2005023I2 (no) 1989-11-28 2005-09-21 Palonosetron HCI

Country Status (23)

Country Link
US (1) US5202333A (no)
EP (1) EP0430190B1 (no)
JP (1) JPH0662607B2 (no)
KR (1) KR970007917B1 (no)
AT (1) ATE124698T1 (no)
AU (1) AU642178B2 (no)
BR (1) BR1100680A (no)
CA (1) CA2030718C (no)
DE (2) DE69020694T2 (no)
DK (1) DK0430190T3 (no)
ES (1) ES2075121T3 (no)
FI (1) FI98367C (no)
HK (1) HK36097A (no)
HU (1) HU218654B (no)
IE (1) IE68434B1 (no)
IL (2) IL110622A (no)
LU (1) LU91162I2 (no)
NL (1) NL300194I2 (no)
NO (2) NO175309C (no)
NZ (1) NZ236225A (no)
PL (3) PL166272B1 (no)
PT (1) PT96001B (no)
ZA (1) ZA909529B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
US5491148A (en) * 1991-04-26 1996-02-13 Syntex (U.S.A.) Inc. Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
ES2179831T3 (es) * 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
WO1995024183A1 (en) * 1994-03-07 1995-09-14 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
US20030113273A1 (en) * 1996-06-17 2003-06-19 Patton John S. Methods and compositions for pulmonary delivery of insulin
GB2288732B (en) * 1994-04-13 1998-04-29 Quadrant Holdings Cambridge Pharmaceutical compositions
EP0759939B1 (en) * 1994-05-18 2005-07-20 Nektar Therapeutics Methods and compositions for the dry powder formulation of interferons
US5567818A (en) * 1994-07-08 1996-10-22 Syntex (U.S.A.) Inc. Processes for preparing 2-(1-azabicyclo[2.2.2]oct-3-yl)-1H-benz[de] isoquinolin-1-one derivatives and intermediates useful therein
US5510486A (en) * 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
US5492914A (en) * 1994-07-28 1996-02-20 Syntex (U.S.A.) Inc. 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US5723103A (en) * 1994-12-09 1998-03-03 Vanderbilt University Substituted benzamides and radioligand analogs and methods of use
US20030035778A1 (en) * 1997-07-14 2003-02-20 Robert Platz Methods and compositions for the dry powder formulation of interferon
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
WO2003072578A1 (en) * 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
CN100336508C (zh) * 2005-02-23 2007-09-12 重庆医药工业研究院有限责任公司 一种稳定的帕洛诺司琼注射液
US20070031342A1 (en) * 2005-06-22 2007-02-08 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8614225B2 (en) * 2006-08-30 2013-12-24 Dr. Reddy's Laboratories Limited Process for the purification of palonosetron or its salt
US7737280B2 (en) 2006-10-23 2010-06-15 Sicor Inc. Processes for preparing palonosetron salts
HRP20090341T1 (hr) * 2006-10-24 2009-07-31 Helsinn Healthcare S.A. Mekane kapsule koje sadrže palonosetron hidroksiklorid s poboljšanom stabilnosti i bioraspoloživosti
EP2099298A4 (en) * 2006-12-07 2010-01-06 Helsinn Healthcare Sa CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE
WO2008146283A2 (en) * 2007-05-29 2008-12-04 Chemagis Ltd. Novel palonosetron salts and processes for preparation and purification thereof
US20090227623A1 (en) * 2007-09-15 2009-09-10 Protia, Llc Deuterium-enriched palosetron
CN101157691B (zh) * 2007-10-18 2011-01-12 杭州九源基因工程有限公司 一种盐酸帕洛诺司琼的生产工艺
AR069625A1 (es) * 2007-12-13 2010-02-03 Glenmark Generics Ltd Base libre de palonosetron y procedimiento para su preparacion
WO2009087643A1 (en) * 2008-01-11 2009-07-16 Natco Pharma Limited Novel crystalline forms of palonosetron hydrochloride
WO2009136405A1 (en) * 2008-05-05 2009-11-12 Natco Pharma Limited High purity palonosetron base and its solid state characteristics
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100099701A1 (en) * 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
WO2010056656A2 (en) * 2008-11-11 2010-05-20 Dr. Reddy's Laboratories Ltd. Preparation of crystalline palonosetron hydrochloride
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
EP2370064A4 (en) * 2008-12-11 2012-09-19 A P Pharma Inc METHOD FOR INCREASING THE STABILITY OF POLYORTHOESTERS AND THEIR FORMULATIONS
CN101851233B (zh) * 2009-04-03 2013-03-06 四川滇虹医药开发有限公司 盐酸帕洛诺司琼和其前体化合物及制备
CN101849904A (zh) * 2009-04-03 2010-10-06 南京长澳医药科技有限公司 一种帕洛诺司琼注射液及其制备方法
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
KR101779991B1 (ko) 2009-05-20 2017-09-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
EP2448936A2 (en) 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Processes for the preparation of form i and form ii of palonosetron hydrochloride
CA2767233A1 (en) 2009-07-14 2011-01-20 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
WO2011013095A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Processes for the preparation of palonosetron
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2744497B1 (en) 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
CN102688185B (zh) * 2012-06-01 2013-07-10 齐鲁制药(海南)有限公司 一种稳定的帕洛诺司琼注射液及其制备方法
WO2015099381A1 (ko) 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2018200387A1 (en) 2017-04-24 2018-11-01 Chase Therapeutics Corporation Compositions and method for treating depression
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. Novel triple combination formulations for antiemetic therapy
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633612A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3341528A (en) * 1963-11-07 1967-09-12 Warner Lambert Pharmaceutical Substituted benzoquinolines
US3896132A (en) * 1969-08-19 1975-07-22 Hoffmann La Roche Process for preparing 1,2,3,8,9,9a-hexahydro-5,6-dialkoxy-1-alkyl-benzo(d,e)quinolin-7-ore compounds
US4309543A (en) * 1980-03-17 1982-01-05 Dynapol Process for preparing cyclic amides
EP0093488A3 (en) * 1982-03-18 1984-05-23 Beecham Group Plc Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them
US4571396A (en) * 1984-04-16 1986-02-18 Warner-Lambert Company Antibacterial agents
WO1988004292A1 (en) * 1986-12-11 1988-06-16 The Upjohn Company Antipsychotic amino-polyhydro-benz-(iso)quinolines and intermediates
EP0315390B1 (en) * 1987-11-04 1994-07-20 Beecham Group Plc Novel 4-oxobenzotriazines and 4-oxoquinazolines
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
AU7618991A (en) * 1990-05-14 1991-11-14 Syntex (U.S.A.) Inc. Novel tricyclic compounds
US5189041A (en) * 1990-11-16 1993-02-23 Syntex (U.S.A.) Inc. Tricyclic 5-ht3 receptor antagonists

Also Published As

Publication number Publication date
FI905839A0 (fi) 1990-11-27
BR1100680A (pt) 2000-02-08
IE904269A1 (en) 1991-06-05
ES2075121T3 (es) 1995-10-01
US5202333A (en) 1993-04-13
JPH03176486A (ja) 1991-07-31
FI905839L (fi) 1991-05-29
DK0430190T3 (da) 1995-08-21
NO175309B (no) 1994-06-20
IL96486A0 (en) 1991-08-16
JPH0662607B2 (ja) 1994-08-17
NO2005023I1 (no) 2005-10-03
HU907660D0 (en) 1991-06-28
DE122005000027I2 (de) 2006-03-16
KR910009699A (ko) 1991-06-28
PL166277B1 (pl) 1995-04-28
FI98367C (fi) 1997-06-10
DE69020694T2 (de) 1996-01-18
PT96001B (pt) 1998-01-30
NO905120L (no) 1991-05-29
ZA909529B (en) 1992-08-26
CA2030718C (en) 1998-05-12
NL300194I1 (nl) 2005-07-01
LU91162I2 (fr) 2005-06-20
PT96001A (pt) 1991-09-30
PL166272B1 (pl) 1995-04-28
HK36097A (en) 1997-03-27
NZ236225A (en) 1992-09-25
NO905120D0 (no) 1990-11-27
IL110622A (en) 1995-03-30
AU6696390A (en) 1991-06-06
NO2005023I2 (no) 2009-10-05
NL300194I2 (nl) 2005-07-01
PL287961A1 (en) 1991-12-02
IL96486A (en) 1995-03-30
EP0430190A3 (en) 1992-01-22
PL166267B1 (pl) 1995-04-28
KR970007917B1 (ko) 1997-05-17
AU642178B2 (en) 1993-10-14
EP0430190B1 (en) 1995-07-05
ATE124698T1 (de) 1995-07-15
HU218654B (hu) 2000-10-28
CA2030718A1 (en) 1991-05-29
DE122005000027I1 (de) 2005-08-04
DE69020694D1 (de) 1995-08-10
EP0430190A2 (en) 1991-06-05
IE68434B1 (en) 1996-06-12
HUT56368A (en) 1991-08-28
FI98367B (fi) 1997-02-28

Similar Documents

Publication Publication Date Title
NO175309C (no) Analogifremgangsmåte for fremstilling av nye, terapeutisk virksomme tricykliske, nitrogenholdige forbindelser
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
RU95101430A (ru) Производные 1-бифенилметилимидазола, их получение, фармацевтическая композиция, способ лечения или профилактики гипертонии
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
PT719253E (pt) Piperidinas 3-amino-5-carboxi-substituidas e pirrolidinas 3-amino-4-carboxi-substituidas como antagonistas de taquicinina
HUT56370A (en) Process for producing tricyclic carbapenem derivatives and pharmaceutical compositions comprising such compounds as active ingredient
DE69428142D1 (de) Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
DK0453042T3 (da) Hidtil ukendte 2 9-disubstituerede 4H-pyhrido[1 2-a]pyridin-4-oner
CA2036905A1 (en) Condensed thiazole compounds, their production and use
RU95104939A (ru) Тетрациклические соединения, способ их получения и промежуточные соединения для этого и применение их в качестве противоопухолевых веществ
EP0604352A3 (en) Aryl substituted heterocyclic compounds.
EP0604355A3 (en) Alkyl substituted heterocyclic compounds.
EA199700287A1 (ru) Бензамиды для лечения нейродегенеративных заболеваний
FI891807A0 (fi) Menetelmä terapeuttisesti aktiivisten oktahydropyrrolo-pyratsino/2,1-i/indol-2-oni-johdannaisten valmistamiseksi
PT89492A (pt) Processo de preparacao de novos derivados de tioformamida terapeuticamente activos
RU95105338A (ru) Трициклические цефемсульфоны, способ их получения, композиция
WO1997029078A1 (en) Cyclic amic acid derivatives
WO1997029077A1 (fr) Derives amides substitues
NO920441L (no) Tnf-inhibitorer
RU94035756A (ru) Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: ALOXI 250 MIKROGRAM INJEKSJONSVAESKE, OPPLOSNING; NAT. REG. NO/DATE: EU/1/04/306/001/NO 20050420; FIRST REG. NO/DATE: EU , EU/1/04/306/001/NO 20050322

Spc suppl protection certif: 2005023

Filing date: 20050921

Extension date: 20151127

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: ALOXI 250 MIKROGRAM INJEKSJONSVAESKE, OPPLOSNING; NAT. REG. NO/DATE: EU/1/04/306/001/NO 20050420; FIRST REG. NO/DATE: EU , EU/1/04/306/001/NO 20050322

Spc suppl protection certif: 2005023

Filing date: 20050921

Extension date: 20151127

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2005023

Effective date: 20151127